Skip to content

Effect of gluten free diet in treatment of IBS

The efficacy of gluten free diet on clinical symptoms and signs, quality of life, and inflammatory factors in patients with irritable bowel syndrome under low FODMAP (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols) diet

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20100524004010N26
Enrollment
40
Registered
2018-10-20
Start date
2017-09-22
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrom. Other diseases of intestines

Interventions

Intervention 1: Intervention group: 1) Group I: will receive food products with 8g/day gluten for first 2 weeks, 16g/day gluten for second 2 weeks, following 32g/day gluten for third 2 weeks. Interven

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 18-65 years Patients with irritable bowel syndrome, according to gastroenterologist diagnosed according to the ROME- IV criteria (1.Improvement with defecation 2.Onset associated with a change in stool frequency 3.Onset associated with a change in stool form (appearance) At least three days a month, three months a year and no pathological findings in the clinical investigating) lack of any organic intestinal disease(diagnosed by last 5 years ago colonoscopy) and intestinal infections(diagnosed by stool culture). No medical history of chronic gastrointestinal and colorectal disease Absence of any major bowel surgery Absence of regular use of laxatives or antidiarrheal drugs No chronic use of antibiotics, corticosteroids and immunosuppressants No usage of drugs that modifying the digestive motility such as metoclopramide, cisapride, diphenoxylate,… No usage of drugs that increased bleeding of intestinal mucosa such as aspirin, warfarin, heparin,… No history of breast cancer in patient or in first-degree relatives of a person Absence of severe mental or behavioral disorder Absence of nicotine and its derivatives use in last 6 months No usage of NSAIDs and aspirin in last week(influence on gut permeability)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Age. Timepoint: Beginning of study. Method of measurement: Question.;Gender. Timepoint: Beginning of study. Method of measurement: Observation.;Weight. Timepoint: Beginning and end of study. Method of measurement: Balance.;Height. Timepoint: Beginning and end of study. Method of measurement: Meter.;BMI. Timepoint: Beginning and end of study. Method of measurement: Calculation.

Secondary

MeasureTime frame
Smoking. Timepoint: Beginning of study. Method of measurement: Question.;Type of diet. Timepoint: Beginning and end of study. Method of measurement: Data collection form.;Total Calorie Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Carbohydrate Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Protein Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Fat Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Fiber Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total MUFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total PUFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total SFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;IL-6. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;INF-?. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Azita Hekmatdoost

Shahid Beheshti University of Medical Sciences

A_hekmat2000@yahoo.com+98 21 2237 6480

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026